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There would appear to be no evidence in the litera- 
ture that, for &agonists, particle size distribution is 
more important than total “respirable dose”. Respir- 
able dose has various definitions: ranging from parti- 
cles ~3 pm, to the fraction of particles ~5 ,um, or even 
<6*8ym. This confusion may be because respirable 
dose has never been adequately defined. Indeed, this 
may be one of the reasons why central and peripheral 
effects cannot be distinguished when the ‘so-called’ 
respirable dose is changed. 
Therefore, consideration needs to be given as to 
what dose fraction represents the likely respirable 
dose, before the effects of changing it can be studied. 
Three separate studies, which used a pressurised 
metered dose inhaler (pMD1) (l), a dry powder 
inhaler (DPI) (2), or a nebuliser (3) to generate an 
aerosol, all reached the same conclusion, namely that 
when comparing the effects of small (~5,~rn) and 
large (>5j~m) particles on measurements of lung 
function, the small particles had a greater effect. 
However, since large, or even coarse, particles 
also had a significant effect, using a cut-off point of 
5,~rn to define the respirable dose is probably too 
simplistic. 
The first study (l), which examined the effect of 
particle size of terbutaline from a pMD1 on the mean 
change in forced expiratory volume in 1 second 
(FEV,), showed that while particles <5,~~rn had a 
significantly greater effect on mean improLement in 
FEV,, larger particles (up to 15 ,um) also improved 
this measure of lung function. In the study by Persson 
& WirCn (2), which used a DPI, the percentage of 
particles ~5 ,um were 1, 8 and 18% of the fixed total 
dose. The results showed only a weak correlation 
between the proportion of particles <5,um and lung 
function. The third study (3), which used a nebuliser, 
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again used different percentages of particles ~5 ,um 
within the dose, in this case 20, 50 and 80%. The 
results showed that whilst increasing the percentage 
of particles ~5 pm improved the clinical outcome, this 
was only significant when 80% of the particles were 
c5prn. Thus, these three studies reinforce the obser- 
vation that while it is better to have small particles, an 
arbitrary cut-off size of <5pm may not be appropri- 
ate as larger particles also contribute to the effect. In 
actual fact, a simple cut-off value is unlikely to define 
the respirable dose, which may be better defined from 
a probability ascribed to different particles sizes. 
Another study (4) showed that reducing the par- 
ticle size of the aerosol increased the dose of drug 
deposited in the lung, which also supports the view 
that total particle dose is more important than 
particle size distribution. 
Using a nebuliser, Johnson, et al. (5) compared the 
effects of small (3.3,~m) arid ‘large (7-7,~~rn) particles 
on lung function in 8 adults with moderate to severe 
asthma. The total dose reaching the lung with the 
small particles was three times that with the large 
particles (Fig. 1). The relative dose distribution in 
the central, intermediate and peripheral regions of 
the lung appeared almost identical for the two 
nebulisers. 
Another study (6) also compared the effects of 
small (1.4pm) and large (5.5 pm) particles on lung 
function, but used a fixed lung dose (i.e. the number 
of small and large particles reaching the lung were the 
same). In this study, both distribution and bronchodi- 
lation were similar with the two particle sizes. This 
indicates that reducing particle size results in a higher 
lung dose, but not in differential deposition. 
Zanen et al. (7) also studied clinical effect in 
relation to particle size, but instead of using poly- 
disperse aerosols (as in the previous studies), mono- 
disperse aerosols with emitted particles sized 1.5, 
2.8 or 5pm were used. There was a significantly 
(p<O*OOl) greater improvement in FEV, with the 2.8 
vs 5,~~rn particles, and there was also a larger im- 
provement with the 2.8 vs 1.5,~~rn particles. It was 
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FIG. 1. Optimal particle size of a ,$-agonist for 
lung deposition and distribution. 
concluded that the most suitable particle size for a 
&agonist aerosol formulation was approximately 
3 pm. Pate1 et al. (8) also reported similar results 
using a monodisperse aerosol. 
What can be concluded from these studies? First, 
increasing the proportion of particles ~5 pm increases 
the lung dose, which in turn increases the effect of a 
&agonist on lung function. If, however, the lung 
dose is fixed, then increasing the fraction of small 
particles has no effect. Second, aerosols containing 
3 pm particles appear to be more effective than those 
containing 5,um particles. With a fixed lung dose, 
however, there is no difference in either deposition or 
effect with the two different particle sizes. There is no 
clinical evidence to support beneficial effects of 
increased lung penetration with reduced particle size. 
The problem of defining respirable dose has 
already been discussed. It may, therefore, be more 
appropriate to use a probability-based distribution 
technique that takes the statistical probability of lung 
deposition for any given particle size into account. 
Alternatively, we recently compared the distribution 
of particles from a spacer using a standard impactor 
‘throat’ with that from the cast of an adult airway 
that extended from the lips to the main stem bronchi 
(9). The dose passing to the level of the bronchi can 
be considered a relevant in vitro estimate of the 
respirable dose. The bias introduced when a single 
cut-off is used to defined the respirable dose is 
illustrated when the particle size distribution of the 
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dose actually reaching the bronchial level through 
such cast is analysed: the major fraction of particles 
14.7 ,um reach the bronchi, but there is also a 
significant proportion of larger particles, and this 
mirrors the clinical data. Therefore, to understand 
drug deposition and distribution, perhaps the term 
respirable dose should be re-defined. The human cast 
method may be useful to define the in vitro correlate 
of the dose reaching the lung, and could be developed 
for each age group, because results obtained with an 
adult model cannot be extrapolated to children or 
infants. 
In summary, respirable dose should not be defined 
using a simple cut-off particle size; it may be repre- 
sented by a particle size probability distribution; and 
using human airway replicates may improve in vitro 
estimates of the lung dose. 
References 
1. Rees PJ, Clark TJH, Moren F. The importance of 
particle size in response to inhaled bronchodilators. Eur 
J Respir Dis 1982; 63 (Suppl): 73-78. 
2. Persson G, Wiren JE. The bronchodilator response from 
inhaled terbutaline is influenced’by the mass of small 
particles: a study on a dry powder inhaler (Turbuhaler). 
Eur Respir J 1989; 2: 253-6. 
3. Clay MM, Pavia D, Clarke SW. Effect of aerosol 
particle size on bronchodilatation with nebulised terbu- 
taline in asthmatic subjects. Thorax 1986; 41: 364368. 
4. Clay MM, Clarke SW. Effect of nebulised aerosol size 
on lung deposition in patients with mild asthma. Thorax 
1987; 42: 190-194. 
5. Johnson M, Newman SP, Bloom R, Talaee N, Clarke 
SW. Delivery of albuterol and ipratropium bromide 
from two nebulizer systems in chronic stable asthma. 
Chest 1989; 96: l-10. 
6. Mitchell DM, Solomon MA, Tolfree S E, Short M, 
Spiro SG. Effect of particle size of bronchodilator aero- 
sols on lung distribution and pulmonary function in 
patients with chronic asthma. Thorax 1987; 42: 4577461. 
7. Zanen P, Go TL, Lammers J-WJ. The optimal particle 
size for &adrenergic aerosols in mild asthmatics. Znt J 
Pharm 1994; 107: 21 l-217. 
8. Pate1 P, Mukai D, Wilson AF. Dose-response effects of 
two sizes of monodisperse isoproterenol in mild asthma. 
Am Rev Respir Dis 1990; 141: 357-360. 
9. Bisgaard H. Delivery of inhaled medication to children. 
J Asthmu 1997; 34: 443468. 
